REDWOOD CITY, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a world chief in minimally invasive remedies for extreme lung illness, as we speak introduced the corporate might be collaborating in two upcoming investor conferences in New York.
Pulmonx administration is scheduled to take part in a hearth chat at the Stifel Healthcare Conference on Wednesday, November 16, 2022, at 8:00AM ET. Interested events might entry a dwell and archived webcast of the occasion on the “Investors” part of the Pulmonx web site at https://investors.pulmonx.com/.
Pulmonx administration will even be collaborating in investor conferences at the Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 17, 2022.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a world chief in minimally invasive remedies for extreme lung illness. Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System and StratX® Lung Analysis Platform are designed to assess and deal with sufferers with extreme emphysema/COPD who regardless of medical administration are nonetheless profoundly symptomatic. Pulmonx acquired FDA premarket approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially out there in additional than 25 international locations, with over 100,000 valves used to deal with greater than 25,000 sufferers. For extra info on the Zephyr Valves and the corporate, please go to www.Pulmonx.com.
Pulmonx®, Chartis®, StratX®, and Zephyr® are registered logos of Pulmonx Corporation.
Contact
Brian Johnston
Gilmartin Group
traders@pulmonx.com
